Asset Details
Do you wish to reserve the book?
A new door opens, but it is essential to accumulate further clinical evidence to control heart failure in diabetes with preserved ejection fraction
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A new door opens, but it is essential to accumulate further clinical evidence to control heart failure in diabetes with preserved ejection fraction
Do you wish to request the book?
A new door opens, but it is essential to accumulate further clinical evidence to control heart failure in diabetes with preserved ejection fraction
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A new door opens, but it is essential to accumulate further clinical evidence to control heart failure in diabetes with preserved ejection fraction
2019
Overview
[...]the risk of first admission for HF was 116.6 per 1,000 patient‐years in diabetes patients with HFpEF, and 155.4 per 1,000 patient‐years in diabetes patients with HFrEF. [...]compared with individuals without diabetes, the incidence of HHF was reported to be almost doubled in patients with diabetes independent of HFpEF or HFrEF (CHARM). Prevention of Heart Failure in the Treatment of Sodium–Glucose Cotransporter 2 Inhibitors Recently, a sodium–glucose cotransporter 2 inhibitor has shown unexpected cardiorenal benefits in large‐scale clinical trials among type 2 diabetes patients with either established cardiovascular diseases or multiple cardiovascular risk factors in the Empagliflozin Cardiovascular Outcome Event Trial in type 2 Diabetes Mellitus Patients‐Removing Excess Glucose (EMPA‐REG OUTCOME) study. [...]both women and/or older patients with diabetes have a higher risk for HFpEF. [...]a new approach to the diagnosis and treatment of HFpEF in diabetes will be an important area in clinical diabetes.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
